EUVIMEDEUVIMED entdecken
Multizentrische StudieBeobachtungsstudieOpen Access · CC BY 4.0

Residual Disease Burden Among European Patients With Inflammatory Bowel Disease: A Real-World Survey

Johan Burisch iD, Ailsa Hart iD, Andreas Sturm iD, Christine Rudolph iD, Rachael Meadows iD, Anna Jus iD, Fatima Dawod iD, Haridarshan Patel iD, Alessandro Armuzzi iD

Inflammatory Bowel Diseases · 06.02.2025 · 31 (2) · 411-424

DOI: 10.1093/ibd/izae119 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift Inflammatory Bowel Diseases, online erschienen am 07.06.2024. Verfasst von Johan Burisch und 8 weiteren Autor:innen. Beteiligte Einrichtung: Gastrounit, Medical Division, Copenhagen University Hospital - Amager and Hvidovre, Hvidovre, Denmark. Hauptthemen laut MEDLINE: Colitis, Ulcerative, Cost of Illness, Crohn Disease, Inflammatory Bowel Diseases. Die Arbeit wurde bisher 21-mal zitiert (Crossref) und nennt 43 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: IBD Disease Specific Programme.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Understanding disease burden is imperative for improving inflammatory bowel disease (IBD) management. This real-world survey investigated residual disease burden and treatment satisfaction among European patients with moderate-to-severe ulcerative colitis (UC) and Crohn’s disease (CD).

Methods

The Adelphi Real World IBD Disease Specific Programme was a multinational, cross-sectional survey with retrospective collection of patient- and physician-reported data on disease burden and management. Between October 2020 and March 2021, participating gastroenterologists recruited their next 7 (UC) and 8 (CD) eligible patients and reported demographics and clinical characteristics. Patients completed symptom, health-related quality of life (HRQoL), and treatment satisfaction questionnaires. Data were adjusted for confounding variables and compared between patients in remission (clinical remission, endoscopic remission, or both) and not in remission.

Results

Overall, 1040 patients (UC, n = 502; CD, n = 538) were included. Although most patients were in remission (UC, 66.1%; CD, 69.5%), most still reported symptoms (UC, 63.7%; CD, 74.1%), including flatulence, fatigue/tiredness, and abdominal pain/distension. In UC, there were no significant differences in the likelihood of experiencing 7 of 23 symptoms between patients in remission and not in remission. In CD, there was no significant difference in 19 of 23 symptoms between patients in remission and not in remission. Several symptoms were significantly associated with reduced HRQoL. HRQoL was significantly better among patients in remission than not in remission.

Conclusions

Patients with IBD, both in remission and not in remission, experience residual symptoms that impair HRQoL. Comprehensive endpoints, incorporating HRQoL and patients’ perspectives, and improved treatments are needed to address residual disease and patients’ needs.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Colitis, UlcerativeCost of IllnessCrohn DiseaseInflammatory Bowel DiseasesPatient SatisfactionQuality of LifeAdultFemaleHumansMaleMiddle AgedYoung AdultCross-Sectional StudiesEuropeRemission InductionRetrospective StudiesSeverity of Illness IndexSurveys and Questionnaires

Stichwörter der Autor:innen

comprehensive disease controlhealth-related quality of lifeinflammatory bowel diseasepatient-reported outcomesreal-world survey

Autor:innen und Institutionen

  • Gastrounit, Medical Division, Copenhagen University Hospital - Amager and Hvidovre, Hvidovre, Denmark.
  • Copenhagen Center for Inflammatory Bowel Disease in Children, Adolescents and Adults, Copenhagen University Hospital - Amager and Hvidovre, Hvidovre, Denmark.
  • Department of Clinical Medicine, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark.
  • Inflammatory Bowel Disease Unit, St Mark's Hospital, Harrow, United Kingdom.
  • Department of Internal Medicine - Gastroenterology, German Red Cross Hospital Berlin, Berlin, Germany.
  • Galapagos NV, Leiden, Netherlands.

ORCID-Profile: Johan Burisch, Ailsa Hart, Andreas Sturm, Christine Rudolph, Rachael Meadows, Anna Jus, Fatima Dawod, Haridarshan Patel, Alessandro Armuzzi

Förderung

  • IBD Disease Specific Programme

Zitieren

APA

Burisch, J., Hart, A., Sturm, A., Rudolph, C., Meadows, R., Jus, A., Dawod, F., Patel, H., & Armuzzi, A. (2025). Residual Disease Burden Among European Patients With Inflammatory Bowel Disease: A Real-World Survey. Inflammatory Bowel Diseases, 31(2), 411-424. https://doi.org/10.1093/ibd/izae119

Vancouver

Burisch J, Hart A, Sturm A, Rudolph C, Meadows R, Jus A, et al. Residual Disease Burden Among European Patients With Inflammatory Bowel Disease: A Real-World Survey. Inflammatory Bowel Diseases. 2025;31(2):411-424. doi:10.1093/ibd/izae119

BibTeX
@article{Burisch2025,
  author = {Burisch, Johan and Hart, Ailsa and Sturm, Andreas and Rudolph, Christine and Meadows, Rachael and Jus, Anna and Dawod, Fatima and Patel, Haridarshan and Armuzzi, Alessandro},
  title = {Residual Disease Burden Among European Patients With Inflammatory Bowel Disease: A Real-World Survey},
  journal = {Inflammatory Bowel Diseases},
  year = {2025},
  volume = {31},
  number = {2},
  pages = {411--424},
  doi = {10.1093/ibd/izae119}
}
Kostenlos starten →